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Abstract
Background: The integration of HIV-1 DNA into cellular chromatin is required for high levels of
viral gene expression and for the production of new virions. However, the majority of HIV-1 DNA
remains unintegrated and is generally considered a replicative dead-end. A limited amount of early
gene expression from unintegrated DNA has been reported, but viral replication does not proceed
further in cells which contain only unintegrated DNA. Multiple infection of cells is common, and
cells that are productively infected with an integrated provirus frequently also contain unintegrated
HIV-1 DNA. Here we examine the influence of an integrated provirus on unintegrated HIV-1 DNA
(uDNA).
Results:  We employed reporter viruses and quantitative real time PCR to examine gene
expression and virus replication during coinfection with integrating and non-integrating HIV-1.
Most cells which contained only uDNA displayed no detected expression from fluorescent
reporter genes inserted into early (Rev-independent) and late (Rev-dependent) locations in the
HIV-1 genome. Coinfection with an integrated provirus resulted in a several fold increase in the
number of cells displaying uDNA early gene expression and efficiently drove uDNA into late gene
expression. We found that coinfection generates virions which package and deliver uDNA-derived
genomes into cells; in this way uDNA completes its replication cycle by viral complementation.
uDNA-derived genomes undergo recombination with the integrated provirus-derived genomes
during second round infection.
Conclusion: This novel mode of retroviral replication allows survival of viruses which would
otherwise be lost because of a failure to integrate, amplifies the effective amount of cellular
coinfection, increases the replicating HIV-1 gene pool, and enhances the opportunity for
diversification through errors of polymerization and recombination.
Background
Integration of the retroviral cDNA into cellular chromatin
is a basic feature of retroviral replication [1-3] and is
mediated by the viral integrase enzyme, a product of the
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pol gene whose substrate is a linear form of viral DNA.
Chromatin supports the high levels of gene expression
necessary for production of new virions and completion
of the viral life cycle. Integration also ensures that the viral
genome will persist for the life of the cell. When viral
latency follows integration, one consequence is viral per-
sistence in the face of highly suppressive antiviral therapy
[4,5]. The integration process provides a target for the
development of antiviral drugs [6].
When integration fails, virus replication is thought to be
irretrievably lost, since unintegrated DNA (uDNA) by
itself evidently does not support the level of gene expres-
sion necessary for virus production [7-11]. Thus uDNA is
considered a replicative dead-end. Interestingly, in vivo
and in cell culture HIV-1 integration has a very high fail-
ure rate, resulting in the accumulation of up to two orders
of magnitude more uDNA than integrated viral DNA
(iDNA) within cells [12]. HIV-1 infection in vitro [13-18]
and in vivo [5,12,14,19-26] results in an abundance of
uDNA regardless of cell type and activation status. In
blood [5,19,20], lymphoid tissue [5,12] and brain [25,26]
uDNA is up to 100 times more abundant than integrated
DNA (iDNA). uDNA accumulates in both activated and
quiescent T lymphocytes [5,14,19], in monocytes [21]
and in patients with high or low viral loads [22,23]. HIV-
1 DNA in vivo has been described as primarily a stable
extrachromasomal episome [19,24]. Since reverse tran-
scription destroys the RNA template, each copy of uDNA
and iDNA represents a unique infection event with a
potentially divergent genetic sequence.
Both linear and circular forms of uDNA accumulate in
cells [27-29]. Linear DNA is quickly degraded within
dividing T cells, with a half-life of less than one day [30],
but is more stable in resting T cells [31], macrophages [32]
and other non-dividing cells [33]. On the other hand, cir-
cular uDNA is highly stable and evidently lost only
through cell death or dilution during cell division
[30,34,35]. Importantly, both linear and circular uDNA
are transcriptionally active [36]. Gene expression from
uDNA has generally been investigated through the use of
integrase inhibitor drugs or using viruses with mutations
in the catalytic domain of integrase (Class I mutations)
which prevent HIV-1 integration while preserving the
ability of the virus to enter cells, uncoat and perform
reverse transcription.
HIV-1 gene expression is divided into early and late
phases, and only early protein products Tat [8,11,37] and
Nef [32,37] have been detected in cells containing only
uDNA. Late gene expression, requiring accumulation of
sufficient Rev to direct the export of singly spliced and
unspliced mRNA from the nucleus, does not occur at high
enough a level to allow for virion production from uDNA
[37,38]. Pre-integration DNA in activated T cells and
transformed T cell lines expresses both early and late RNA,
though only Tat and Nef are apparently translated [38].
Prior to integration in resting T cells, uDNA can express
Tat and Nef proteins at levels which promote cell activa-
tion and enhance productive infection, suggesting a
potential role in viral replication [37]. In macrophages,
uDNA can remain transcriptionally active for at least 30
days [32]. Studies employing bulk analysis of cells have
shown that uDNA is responsive to Tat activation [39].
Additionally, Vpr protein brought into cells within viruses
increases uDNA gene expression of both Tat and Nef
[39,40].
Multiple infection of cells is easily demonstrated in cul-
ture [16-18,41-44] and increases over time through rein-
fection [17,43,45-47]. HIV-1 entry apparently favors
multiple infection, whether through cell-free virus or cell
to cell contact [41,42]. Our previous work has shown that
over several rounds of virus replication in culture or in
human lymphoid tissue in an animal host, multiple infec-
tion proceeds with no observable inhibition [43]. The
outcome is frequent coinfection and a high rate of recom-
bination [43]. Within lymphoid tissues, particularly in
germinal centers, cells are in close proximity, cognate and
non-cognate immune cell contact is ongoing and the local
concentration of virus is much higher than in the blood
[48] favoring multiple infection [49]. Most striking, a
study employing in situ analysis of splenocytes from HIV-
1+ individuals observed an average of 3–4 proviruses per
infected cell, with up to 8 in some cells [50]. Analysis of
the genetic diversity within individual splenocytes could
only be explained by additional unintegrated DNA [28].
More recently, Mattapallil et al. demonstrated that acute
SIV infection results in an average of 1.5 proviruses per
cell [51]. In cell culture experiments, infection at a fre-
quency of 3 integrated proviruses per cell resulted in the
accumulation of 10 times that amount of uDNA within
the cells [16]. A convincing mechanism for abundant
coinfection has been provided by recent descriptions of
the viral synapse, in which contact between infected and
uninfected cells leads to a directed delivery of high num-
bers of virions into cells [52-54].
Together, the documentation of uDNA gene expression
and the presence of uDNA and iDNA together in cells sug-
gests that these two forms of HIV-1 genomes might func-
tionally interact. Here we investigated the influence of an
integrated provirus on the activity and replication of
viruses which fail to integrate.
Results
Single cell analysis of uDNA-directed gene expression
Gene expression from unintegrated DNA has been studied
through bulk analysis of infected cells (RNA assays, west-Retrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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ern blot, etc.) and reporter viruses that employ luciferase,
which is measured on bulk populations of cells
[11,39,40]. Single cell analysis, on the other hand, would
provide information on both the level of gene expression
in individual cells and the number or proportion of cells
containing genetically active uDNA. In order to perform
single cell analysis we employed HIV-1 reporter viruses
containing genes for the fluorescent proteins enhanced
GFP, enhanced YFP, enhanced CFP and DsRedExpress
("DsRedX") [43,55]. GFP, YFP and CFP versions of these
viruses have been previously described [43,55] and con-
tain the reporter gene inserted immediately downstream
of the envelope gene in the position normally occupied by
the early gene nef, which is expressed from an IRES ele-
ment. Schematic diagrams of each reporter virus are pre-
sented in [Additional file 1]. To study gene expression and
virus replication from uDNA, we applied the diketo acid
integrase inhibitor 118-D-24 [56,57] to cells at the time of
infection, or we introduced a D116N Class I active site
mutation [7,11] into the integrase gene of the reporter
viruses. For single round replication experiments we
employed envelope mutant variants which were pseudo-
typed with VSV-G protein [43,55].
We first compared early HIV-1 gene expression in T cells
from integrating and non-integrating viruses, focusing on
the period corresponding to the average in vivo life span of
an infected T cell. We infected cells at a low MOI (≤0.12)
to limit the amount of multiple infection, then analyzed
the cells by flow cytometry at 48 and 72 hours after infec-
tion. Prior bulk analyses of cells have shown that uDNA
expression from early HIV-1 genes is about 2 orders of
magnitude lower than from an integrated provirus
[11,39,40]. Our single cell analysis showed reductions
compared to WT virus in both the number of fluorescent
cells and the level of fluorescence in each cell which were
similar for both the integrase mutation and the integrase
inhibitor (Figure 1). The number of fluorescent cells was
reduced 2.6 to 4 fold vs. WT virus in untreated cells (up to
10 fold reduction was observed in some experiments),
while the level of the reporter expression in fluorescent
cells was reduced 11.7 to 34 fold. The cumulative effect of
fewer cells with active viruses and lower expression per
cell yields an effective reduction in gene expression of
40–125 fold for uDNA vs. integrating virus, a result that is
consistent with the previous bulk analyses. Integrase
inhibitor slightly increased background autofluorescence
from the cells. This is apparent in the rightward shift of the
large GFP-negative population of cells treated with inte-
Gene expression from cells infected with integrating and non-integrating HIV-1 reporter viruses Figure 1
Gene expression from cells infected with integrating and non-integrating HIV-1 reporter viruses. NLENG1-ES-
IRES [43] ("WT-GFP") or an integrase D116N mutant version of NLENG1-ES-IRES ("D116N-GFP"), each pseudotyped with 
VSV-G protein, were used to infect Jurkat cells (4.4 ng p24 on 2 × 10^5 cells) and analyzed by flow cytometry 48 and 72 hours 
after infection. Integrase inhibitor 118-D-24, or DMSO carrier, was applied to some cells at 200 μM at the time of infection 
with integrase-WT virus. Data are representative of several independent experiments. Table shows the percentage of cells that 
were GFP+ ("% Pos.") and the mean fluorescence (MF) of the GFP+ cells divided by the background fluorescence of the GFP-
negative cells ("MF(+/-)"). "Product" is the % Pos. multiplied by the MF(+/-) and represents the overall GFP gene expression 
from the infected cells. Numbers in parentheses represent the fold reduction vs. WT virus. "II" = integrase inhibitor. Dot plots 
show GFP fluorescence in the X axis and arbitrarily chosen red background fluorescence on the Y-axis.
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grase inhibitor in Figure 1. Cells that are not exposed to
virus show the same shift in response to integrase inhibi-
tor (not shown). However the mean fluorescence of the
GFP+ cells treated with integrase inhibitor was higher rel-
ative to background than the cells infected with the inte-
grase mutant. All of this additional fluorescence was
found in a minor population of cells that were as bright as
the cells infected with WT virus, suggesting that integrase
inhibitor had failed to prevent integration in a small
minority of cells.
Interestingly, the level of gene expression increased from
day 2 to day 3, as did the percentage of cells that were flu-
orescent, for both the integrating virus and the non-inte-
grating viruses. The DNA of an integrated virus will be
duplicated and partitioned to each daughter cell, while
uDNA will be diluted by cell division in this rapidly divid-
ing population. Therefore the increase in uDNA gene
expression from day 2 to day 3 indicates that rather than
being rapidly inactivated or only active prior to viral inte-
gration in these cells, uDNA is a source of early HIV-1 gene
expression throughout the average ≤2 day life span of in
vivo infected T cells.
Most uDNA is inactive by itself but is subject to activation 
by an integrated provirus
The co-residence of uDNA and iDNA in cells has been
documented in vivo and in tissue culture [16,18,28]. To
examine uDNA gene expression under this circumstance,
we infected T cells with either a D116N-GFP mutant virus
alone or simultaneously infected the cells with the same
amount of mutant virus plus increasing amounts of a WT-
DsRedX virus (Figure 2A). Each virus was envelope-defec-
tive and pseudotyped with VSV-G protein for single round
infection. As more cells were infected with increasing
amounts of integrating WT-DsRedX virus, more cells dis-
played gene expression from the integrase mutant
D116N-GFP virus. Similar results are obtained by infect-
ing cells sequentially with mutant and WT a day apart,
indicating that this result is not due to viruses adhering to
each other prior to entry (not shown). The percentages of
cells showing gene expression from the D116N-GFP virus
in response to coinfection is graphed in Figure 2B, where
a linear response to increasing WT-DsRedX infection is
evident. Extrapolation to 100% WT-DsRedX infection
suggests a potential 7 fold increase in the number of cells
displaying uDNA-driven GFP fluorescence.
The activation of uDNA is presumably through the effects
of Tat provided by the integrated provirus. To test this we
infected Jurkat and Jurkat-Tat cells, the latter cell line con-
stitutively expressing Tat protein from an integrated plas-
mid [58]. Infection of these two cell lines with identical
amounts of VSV-G pseudotyped virus (which bypasses
differences in CD4 expression) resulted in a very similar
outcome as coinfection between WT and D116N viruses,
confirming the influence of Tat on the number of cells dis-
playing uDNA-directed gene expression (Figure 2C). PCR
analysis showed that Jurkat and Jurkat-Tat cells were
infected with equal amounts of virus (see below).
The mean fluorescence intensity of cells infected with
D116N-GFP virus was increased only an average of 1.5
fold in the coinfected cells compared with cells infected
with just the integrase mutant, and Tat increased the
brightness of D116N infected cells an average of 1.8 fold
(Figure 2D). Thus the primary effect of coinfection and of
Tat is to drive uDNA gene expression when it otherwise
would not occur at levels measurable by GFP expression,
rather than to dramatically increase the level of uDNA
gene expression from viruses that are already active.
DNA qPCR analysis revealed an average of 0.9 uDNA HIV-
1 genomes per cell ("DNA MOI" of 0.9) in both the Jurkat
and J-Tat cells infected with the D116N virus. Jurkat cells
infected with the D116N virus displayed GFP fluorescence
in 5% of cells, which, by Poisson distribution analysis cor-
responds to a "fluorescence MOI" of 0.05, or 18.4 times
less than the actual DNA-based MOI. This indicates that
only a small fraction of uDNA genomes were active to a
level detectable by flow cytometry. In the Jurkat-Tat cells,
on the other hand, 34% of the cells were GFP+, which cor-
responds to a fluorescence MOI (by Poisson analysis) of
0.42, which is nearly half of the DNA MOI of 0.9
genomes/cell.
Late gene expression from uDNA
In order to generate new virions, HIV-1 must transition to
late gene expression by first expressing a threshold level of
Rev protein, which then facilitates export of unspliced and
singly spliced RNA to the cytoplasm. These Rev-depend-
ent late RNA encode late accessory proteins Vpr, Vpu and
Vif, and the structural polyproteins Gag, Pol and Env. Rev-
dependent unspliced RNA molecules are also packaged
into virions as viral genomes [38]. To study late gene
expression from uDNA at the single cell level we created a
dual early-late reporter virus by adding the gene for
murine Heat Stable Antigen (HSA) (a.k.a. murine CD24)
in the vpr region [59] to the WT-GFP and D116N-GFP
viruses. HSA is a cell surface protein that can be detected
with antibodies in flow cytometry. GFP is expressed from
Rev-independent (early) mRNA, and HSA is expressed
from Rev-dependent (late) vpr mRNA. Thus cells infected
with this dual reporter virus will be GFP+HSA- single pos-
itive when the virus is in the early phase of HIV-1 gene
expression, whereas cells containing a virus in the late
Rev-dependent phase of gene expression will be
GFP+HSA+ double positive. Since Vpr protein brought
into cells by infecting virions contributes to gene expres-
sion from uDNA [40], and the vpr gene is deleted in thisRetrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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Activation of uDNA gene expression by coinfection with integrating virus Figure 2
Activation of uDNA gene expression by coinfection with integrating virus. A. Upper panels: 2 × 10^5 Jurkat cells were left 
uninfected (left panel) or infected with increasing amounts of WT-DsRedX virus (5, 20, 60 ng p24 respectively). Lower panels: Cells were 
simultaneously infected with equal amounts of D116N-GFP virus (10 ng p24) and the same amount of WT-DsRedX virus as in the panel 
directly above. Numbers represent the percentage of cells in each indicated quadrant. All viruses were envelope-defective and pseudo-
typed with VSV-G protein to limit viruses to a single round of replication. B. The solid blue line plots the percentage of cells that express 
D116N-associated GFP fluorescence from the lower panels in A (Y axis) as a function of the amount of WT-DsRedX infection (X axis). 
Extrapolation to 100% infection with WT-DsRedX virus implies that 42% of cells are infected with a D116N-GFP virus that is capable of 
generating fluorescence in the presence of a coinfecting integrating virus (dashed lines). C. Effect of Tat on the percentage of cells 
expressing D116N-associated GFP fluorescence. As in Figure 2A-B, viruses were envelope defective and pseudotyped with VSV-G to 
overcome differences in CD4 levels on Jurkat and Jurkat-Tat cells and to limit viruses to a single round of replication. qPCR for HIV-1 
DNA found equal infection of Jurkat and Jurkat-Tat cells with 0.9 HIV-1 genomes/cell by real time DNA qPCR. A nearly 7-fold increase in 
the percentage of cells expressing D116N-associated GFP fluorescence is similar to results of coinfection in panel B and demonstrates 
that Tat is sufficient for the transactivation provided by coinfecting viruses. This experiment is representative of multiple independent 
experiments. D. The increase in mean fluorescence in Jurkat from D116N-GFP virus as a result of coinfection with an integrase-WT virus 
as a result of Tat transactivation in the Jurkat-Tat cell line. Coinfection data represent the mean fluorescence of cells coinfected with 
D116N-GFP and WT-DsRedX viruses divided by the mean fluorescence of cells infected with only D116N-GFP virus.  Data represent 
multiple samples from each of 3 independent experiments. Tat data represent the mean fluorescence of GFP+ Jurkat-Tat cells divided by 
the mean fluorescence of GFP+ Jurkat cells infected with D116N-GFP virus. The average and SD are derived from multiple samples of a 
representative experiment.
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virus, we generated Vpr+ virions by co-transfecting 293T
cells with a Vpr expression plasmid. We observed Vpr
enhancement uDNA gene expression up to 2 fold under
these conditions (not shown).
Analysis of activated T cells infected with an integrase-WT
dual reporter virus showed late gene expression within
50–85% of GFP+ cells 48 hours after infection (76% in
this experiment is typical) (Figure 3A). The overall infec-
tion frequency was 3.9%. Late gene expression was almost
entirely limited to the cells displaying the highest levels of
GFP expression, indicating that during HIV-1 replication
Rev does not down regulate early gene expression. Infec-
tion with equal amounts of an integrase mutant dual
reporter virus resulted in 0.5% GFP+ cells, of which only
6.3% showed late gene expression, consistent with prior
studies on bulk cell populations [37,38] (Figure 3B). To
test the influence of a coinfecting integrating virus we
simultaneously infected T cells with the D116N GFP/HSA
dual reporter virus and a WT-DsRedX virus (which does
not express HSA) and gated on the DsRedX+GFP+ double
positive coinfected cells (Figure 3C). 57% of these coin-
fected cells displayed HSA expression from the integrase
mutant, indicating an efficient switch to late gene expres-
sion by the uDNA. The result was a little lower than
expression from the WT virus; however, since about one-
quarter of WT viruses do not reach late gene expression at
this time point, it is reasonable to assume that these
viruses would be unable to boost a coinfecting virus to
late gene expression, perhaps as a result of inadequate Rev
expression. Indeed, PCR analysis of GFP+HSA- cells
infected with integrase-WT virus showed that many of
Late HIV-1 gene expression from integrating and non-integrating HIV-1 Figure 3
Late HIV-1 gene expression from integrating and non-integrating HIV-1. Activated primary T cells were infected 
with A. a WT-GFP virus, B. a D116N-GFP/HSA dual reporter virus or C. coinfected with the D116N-GFP/HSA dual reporter 
and a WT-DsRedX virus. Cells were analyzed by flow cytometry 48 hours after infection. Upper panels show all infected cells, 
total infection rates, and the gates applied for analysis in the lower panels. Lower panels show Rev-independent early gene 
expression (GFP) vs. Rev-dependent late gene expression (HSA). Gating is on the fluorescent cells in the top panels in order to 
highlight the ratio of cells displaying early (GFP+HSA- cells) to those exhibiting late HIV-1 expression (GFP+HSA+ cells). Data 
are representative of several independent experiments. Similar results are obtained with Jurkat cells.
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these cells contained integrated genomes yet had not tran-
sitioned to late gene expression (not shown).
Completion of a full infectious virus life cycle by uDNA 
through viral complementation
Late gene expression from uDNA begs an important ques-
tion: Do virions generated by an integrated provirus pack-
age functional genomes derived from uDNA, allowing
uDNA to complete its replication cycle and contribute to
the replicating gene pool? To test this notion we per-
formed a 2 cycle virus replication assay, where the first
infection generates "producer" cells that are coinfected
with uDNA and iDNA, and the second generation viruses
from these producer cells are then assayed for their ability
to deliver functional uDNA-derived genomes to "target"
cells. For the remaining series of experiments we
employed viruses containing functional envelope genes
with no virus pseudotyping and infected cells via HIV-1
envelope mediated entry. We infected Jurkat T cells with
D116N-GFP alone or a combination of WT-DsRedX and
D116N-GFP HIV-1. One day after infection we washed
these infected producer cells and treated them with the
broad spectrum protease pronase in order to remove
residual input virus, then placed the cells back in culture
for 1 to 2 days to allow de novo virus production. These
second generation viruses were used to infect Jurkat-Tat
cells which were then analyzed by flow cytometry to assess
the proportion of GFP+ and DsRedX+ cells. Jurkat-Tat
cells were employed as targets in order to activate uDNA
genomes which otherwise would be silent or express
below the threshold of detection, thus providing a more
reliable accounting of infection. Since integrase mutant
viruses are used only as a convenient surrogate for
"unlucky" but otherwise replication competent viruses
which fail to integrate, the use of Tat-containing target
cells improves the relevance of the analysis. As expected,
producer cells infected with only the integrase mutant
released very little to no infectious virus (Figure 4A).
Supernatants from coinfected producer cells treated with
an antiviral protease inhibitor (Indinavir) showed very lit-
tle infectivity, demonstrating a lack of carryover of virus
from the initial infection (Figure 4B). On the other hand,
cells coinfected with WT-DsRedX and D116N-GFP gener-
ated infectious viruses which conferred GFP and DsRedX
fluorescence to target cells (Figure 4C). Application of
reverse transcriptase inhibitors (AZT and Efavirenz) to tar-
get cells prevented the appearance of fluorescence from
both viruses (not shown), demonstrating that the appear-
ance of fluorescence in target cells requires reverse tran-
scription. In some experiments virus stocks were treated
with DNase in order to eliminate possible plasmid con-
tamination, with no effect on the experimental outcome
(not shown). These results establish that uDNA-generated
mRNA is packaged into virions and delivered as a func-
tional replicating genome through complementation by
an integrated provirus.
Efficiency of replication of the uDNA-derived genomes
Next we performed a quantitative analysis of the contribu-
tion of uDNA-derived genomes to the replicating virus
population. By comparing the ratio of GFP+ to DsRedX+
target cells to the GFP+/DsRedX+ ratio in the producer
cells, the efficiency of viral packaging of functional uDNA
genomes can be gauged. Our analysis is based on the fol-
lowing assumptions: Producer cells that are infected with
only WT virus ("W" in Figures 4 and 5) will generate viri-
ons that have only WT genomes in them, while the cells
infected with only the integrase mutant will generate little
or no virus, and so are ignored in calculations. Cells that
are coinfected with WT and D116N viruses ("C" in Figures
4 and 5) will generate a population of virions containing
both WT and integrase mutant genomes at some
unknown ratio. For example, if coinfected cells package
50% WT and 50% D116N genomes into viruses, then the
output of D116N virions from coinfected cells ("C") is C/
2. The percentage of D116N genomes in the total virus
population from producer cells will be (C/2)/
(W+C)*100. Target cells will be GFP+ and/or DsRedX+ in
a proportion that reflects the ratio of virions containing
functional genomes of either type. Although HIV-1 viri-
ons contain two RNA genomes, which can be derived
from the same or different producer viruses, this diploidy
can be ignored at present since virions will generate only
a single cDNA in target cells and will confer either GFP or
DsRedX fluorescence but not both.
In order to examine the influence of MOI or uDNA/iDNA
ratio on the efficiency of complementation, we infected
producer cells with a constant amount of D116N-GFP
virus and increasing amounts of WT-DsRedX virus, then
transferred viruses to target cells on day 2 after infection of
producer cells (Figure 5A–C). As the amount of WT virus
used to infect producer cells was increased (while holding
the amount of mutant virus constant), the frequency of
coinfected producer cells (C) showing uDNA gene expres-
sion rose (Figure 5A) (similar to the upper right quadrants
in Figure 2A). As predicted, the number of viruses gener-
ated which deliver the mutant genome to target cells
increased in direct proportion to the number of coinfected
producer cells (Figure 5B).
If WT and integrase mutant viruses generate equal
amounts of virion-packaged genomes in the coinfected
cells, then the ratio of GFP to DsRedX in the target cells
should reflect the following: (C/2)/(W+C) in the producer
cells = G/(G+R) in the target cells. Unity in this relation-
ship is represented by the red line in Figure 5C. Surpris-
ingly, at each amount of input virus and ratio of WT-
DsRedX to D116N-GFP viruses used to infect producerRetrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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Completion of the HIV-1 replication cycle by uDNA via coinfection with an integrating virus Figure 4
Completion of the HIV-1 replication cycle by uDNA via coinfection with an integrating virus. Jurkat cells were infected with D116N-GFP 
virus only, washed and incubated with protease to remove residual virus, then 2 days later the resulting culture supernatants were used to infect Jurkat-
Tat target cells. A. Cells containing only uDNA show little infectious virus output. B. Cells that were coinfected with WT-DsRedX and D116N-GFP 
viruses and treated with HIV-1 protease inhibitor Indinavir show little virus output. C. Procedures followed as in B, except no Indinavir was present. Virus 
transfer to Jurkat-Tat target cells results in both DsRedX fluorescence and GFP fluorescence, indicating that infectious viruses were generated which pack-
age and deliver functional genomes derived from unintegrated D116N-GFP DNA within the producer cells. Data are representative of multiple independ-
ent experiments. "C = 3%", "W", "G", "R" refer to figure 5.
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Measurement of the efficiency of uDNA replication during coinfection Figure 5
Measurement of the efficiency of uDNA replication during coinfection. A. The relationship between the infection of producer cells with WT-
DsRedX virus and the presence of producer cells displaying fluorescence from both WT-DsRedX and D116N-GFP viruses. The same amount of D116N-
GFP virus was used to infect each population of cells, yielding 4.5% GFP+ cells without addition of WT-DsRedX virus. As increasing amounts of WT-
DsRedX virus are used to coinfect cells, the percentage of cells displaying both GFP and DsRedX fluorescence increased linearly, as shown. Data were col-
lected day 2 after infection of producer cells, at the time of virus transfer to target cells. Values represent the percentage of producers that were double-
positive (X axis) vs. the percentage of producers that were DsRedX+ (both single and double positive). B. The relationship between the frequency of dou-
ble positive GFP+DsRedX+ producer cells and the frequency of the resulting GFP+ target cells. C. Relationship between the GFP+ producer cells and the 
ratio of D116N-GFP and WT-DsRedX viruses conferred to target cells. The X axis predicts the percentage of viruses generated by producer cells that will 
confer GFP to target cells. The formula for the X axis assumes equal production of D116N-GFP and WT-DsRedX viruses from double positive producer 
cells and production of only DsRedX viruses from DsRedX+ cells. The Y axis presents the percentage of all fluorescent target cells that are GFP+. In the 
target cells, all GFP+ cells (G) and DsRedX+ cells (R) are tallied, and cells which are double positive GFP+DsRedX+ are counted in both categories. The 
red line represents unity between the two formulas, where the assumptions used in the X axis formula are true. D. The experiment presented in A-C was 
repeated using primary activated CD4+ T cells as producers, and the percentage of D116N-GFP and WT-DsRedX in each producer cell population is 
shown to illustrate the wide range of MOI and WT/D116N ratios employed. Blue squares represent producer cells on day 2 after infection and orange cir-
cles represent producer cells on day 3 after infection. Data are aggregated from 3 independent experiments. E. The relationship between producer and 
target cells as in Figure 5C using primary T cell producer cells, showing data from the 3 independent experiments in Figure 5D. F. WT-DsRedX to 
D116N-GFP ratio in the target cells by flow cytometry and DNA PCR, and by RT-PCR on the viruses used to infect them. Numbers represent the ratio of 
DsRedX+ cells to GFP+ cells, or the ratio of WT-DsRedX to D116N-GFP nucleic acid in indicated samples. This experiment is representative of two inde-
pendent experiments. G. Averages and standard deviations for the cumulative data in Figure 5E.
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cells, the ratio of GFP to DsRedX in target cells adhered
closely to this value. WT-GFP and D116N-DsRedX viruses
produced identical results (not shown). Virus containing
another Class I mutation, D64E, generated identical
results as the D116N mutant (not shown).
We next tested this relationship using primary activated
CD4+ T cells as producer cells, transferring virus to target
cells on both day 2 and day 3 after infection of the pro-
ducer cells. After day 3, re-infection of producer cells with
second round viruses would obscure meaningful results
regarding the ratio of uDNA and iDNA genome produc-
tion, so no attempt was made to carry the experiment past
day 3. We infected the producer T cells at a wide range of
MOI (0.004 to 0.063 D116N-GFP, 0.007 to 0.23 WT-
DsRedX based on the percentage of cells fluorescent in
each color by a Poisson distribution formula, and a ratio
of GFP+ to DsRedX+ cells from 0.16 to 24.31) (Figure
5D). As seen in Figures 5E and 5G, the resulting ratios of
GFP+/DsRedX+ target cells adhered well to the rule gener-
ated in Jurkat cells.
To further validate our flow cytometry analysis, we meas-
ured by quantitative real time PCR the GFP and DsRedX
DNA products of reverse transcription in 4 samples of Jur-
kat-Tat target cells with widely varying infection rates and
GFP+/DsRedX+ ratios. We also analyzed by RT-PCR the
DsRedX and GFP genomes within the viruses used to
infect these target cells. Both the ratio of DsRedX to GFP
DNA in the target cells and the RNA content of the viruses
reflected very closely the proportion of cells displaying
GFP and DsRedX fluorescence, confirming that flow anal-
ysis of target cells accurately describes the packaging effi-
ciency of the genomes (Figure 5F).
Phenotypic complementation of a genetic defect during 
productive coinfection
Multiple infection of cells provides the opportunity for
phenotypic complementation through the mixing of pro-
teins in virions. A defective gene in one virus may be com-
plemented by a functional gene in another virus, thus
allowing less fit viruses to persist. HIV-1 may even evolve
towards lower fitness as a result of multiple infection of
cells while still causing disease [60]. In our virus transfer
experiments, typically one half of the GFP+ target cells dis-
played fluorescence as bright as that generated by WT
viruses (compare, for example the relative absence of
bright GFP fluorescence in producer with the cluster of
bright GFP+ target cells in Figure 4C). The appearance of
bright GFP+ target cells suggests that the D116N-GFP viral
genomes had undergone integration in the target cells.
Successful integration by the integrase mutant cDNA
would most likely result from packaging of WT integrase
together with the integrase mutant RNA. To test for inte-
gration we sorted the GFP bright and GFP dim popula-
tions of the single color target cells and analyzed the cells
by real time PCR [13] for integrated and viral DNA (Figure
6). Among the sorted GFP+DsRedX- bright target cells
there were 1.06 integrated genomes per cell, while within
the GFP+DsRedX- dim cells there were only 0.17 inte-
grated genomes per cell. This demonstrates that viruses
with essentially zero fitness can persist through pheno-
typic complementation of a specific defect by a coinfect-
ing virus.
Recombination between uDNA-derived and iDNA-derived 
genomes
Recombination occurs during infection when reverse tran-
scriptase switches templates and generates a cDNA that is
a mosaic of the two co-packaged RNA genomes. Recombi-
nation only occurs between genomes that are co-packaged
into virions, and does not occur during infection of cells
with two different but homozygous viruses. Thus the
appearance of recombinant viruses is a definitive indica-
tion that two different genomes have been packaged into
single virions, infected new cells and undergone reverse
transcription. We developed an experimental system that
allows study of retroviral recombination on any cell type
using flow cytometry [43]. In this system, recombination
within the YFP and CFP genes in reporter viruses generates
a novel sequence that confers GFP fluorescence to target
cells. To test recombination between uDNA-derived and
WT-derived genomes, we infected producer cells with
D116N-YFP and WT-CFP viruses, then analyzed target
cells for CFP, YFP and GFP fluorescence. As seen in Figure
Phenotypic complementation between WT and D116N in  virions Figure 6
Phenotypic complementation between WT and 
D116N in virions. Target cells from virus transfer experi-
ment in Figure 4. Two days after infection of target cells 
bright and dim GFP+ cells were sorted by FACS, then qPCR 
for integrated DNA was performed on the sorted cells. The 
integration of D116N-GFP DNA demonstrates that integrase 
mutant genomes are complemented by WT integrase within 
virions.Retrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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7, GFP+ target cells appeared, demonstrating recombina-
tion between uDNA-derived and iDNA-derived genomes.
Discussion
Here we show that unintegrated HIV-1 can participate in
the replication of HIV-1 and contribute to its diversifica-
tion. We found that when alone in cells, a small fraction
of unintegrated HIV-1 DNA showed spontaneous gene
expression measured by GFP fluorescence, but that
through complementation with Tat from a coinfecting
integrated provirus, a substantial fraction of uDNA was
activated. During coinfection uDNA generated RNA
genomes that were packaged into virions and delivered
into new cells, where they underwent reverse transcrip-
tion, recombination and integration. Although HIV-1
uDNA is not a strong template for gene expression,
uDNA-derived genomes were nevertheless represented at
a substantial level in the replicating pool of viruses, sug-
gesting that replication of unintegrated HIV-1 may be bio-
logically significant.
These findings have broad implications for the replica-
tion, diversification and persistence of HIV-1. Most funda-
mentally, viral sequences that were once believed to be
lost owing to a failure to integrate may in fact be rescued
by viral complementation. Since each copy of uDNA and
iDNA represents a unique infection event with a poten-
tially divergent virus, the rescue of unintegrated viruses
would function to preserve extant viral diversity and
lessen the chance that genetic information is lost through
random drift. An important parameter in the evolutionary
dynamics of HIV-1, the effective population size [61-67],
defined as the number of individuals in a population
which contribute to the next generation, could be sub-
stantially amplified through this mechanism. By rescuing
viruses which would otherwise be lost, complementation
of uDNA greatly increases the effective amount of cellular
coinfection. Coinfection is the prerequisite for the copack-
aging of divergent genomes, and copackaging is the pre-
requisite for recombination, so the opportunity for
recombination is enhanced. This observation provide a
mechanism to explain in situ analysis of splenocytes of
HIV-1 infected individuals showing frequent multiple
infection with co-residence of uDNA and iDNA and
extraordinarily and inexplicably high recombination [50].
Additionally, since each copy of uDNA and iDNA repre-
sents a unique reverse transcription event with the highly
error-prone viral polymerase, the effective amount of
mutation is increased by the preservation of unintegrated
viruses. In conclusion, what has been thought to be a
"bug" in the replication program of HIV-1 (the frequent
failure to integrate) might now be seen as a "feature"
which amplifies viral diversification and promotes sur-
vival of the quasispecies though cooperative interactions
among its members [64,67,68].
The reasons for failure to integrate are not well under-
stood, but there is likely to be a large stochastic compo-
nent, where integrase may simply fail to find a chromatin
target [27]. The proliferation of uDNA is thus not neces-
sarily an indication of inherent defects among the uninte-
grated viruses, but rather this population probably reflects
the replicating virus population as a whole. Other factors
contributing to failure to integrate include possible degra-
dation of linear DNA ends by cellular exonucleases before
integration can occur, preventing integrase-mediated liga-
tion of the viral DNA into the host chromosome. The pre-
integration complex (PIC), comprising the viral cDNA
and several viral proteins including integrase, must be pre-
served intact for integration to succeed. The PIC has a lim-
ited functional life span [69] and can be inactivated by
cellular proteases [70], rendering the viral DNA vulnera-
ble to attack by cellular defense mechanisms, including
nucleases and other enzymes which modify foreign
nucleic acids. Whether uDNA as a whole contains more
Recombination between uDNA-derived and iDNA-derived  genomes Figure 7
Recombination between uDNA-derived and iDNA-
derived genomes. Jurkat cells were simultaneously 
infected with D116N-YFP and WT-CFP viruses and a virus 
transfer experiment performed as in Figure 4. The appear-
ance of GFP+ target cells is strictly dependent upon copack-
aging of YFP and CFP genomes into virions during virus 
assembly in producer cells and reverse transcription during 
second round infection of target cells [43]. Numbers repre-
sent the percentage of cells in each quadrant. Data are repre-
sentative of multiple independent experiments.Retrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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cell-induced damage than iDNA remains to be investi-
gated.
The 3 most common forms of uDNA are linear, 1-LTR cir-
cles and 2-LTR circles [27-29]. Linear DNA predominates
in vivo and in vitro, with a ratio of linear, 1-LTR circles and
2-LTR circles of about 20:9:1, respectively [71-73]. In vivo
most linear uDNA molecules lack the blunt ends neces-
sary for integration [5]. Linear DNA can become circular-
ized by cellular repair mechanisms [1,74,75] within the
cell nucleus; thus the presence of HIV-1 circles is a positive
indication of nuclear import. We have not characterized
which species of uDNA contribute to the replicating pool,
but there is no a priori reason why both linear and circular
uDNA could not generate full length genomes for virion
packaging. All classes of linear and circular uDNA are
probably transcriptionally active, with 1-LTR circles being
more active than 2-LTR circles [36]. Both integrase inhib-
itors and active site integrase mutant HIV-1 generate
excess 2-LTR circular forms compared with WT virus for
reasons that are incompletely understood [8,38], so it is
possible that if 2-LTR circles are particularly efficient tem-
plates for generating packaged genomes, our experimental
system could exaggerate the contribution of uDNA to viral
replication. This does not seem likely, since linear uDNA
predominates over circles. Even though linear uDNA is
quite labile and is lost within a day or two after infection
of activated T cells, the half life of infected T cells in vivo is
of similar length; thus all forms of uDNA, linear and cir-
cular, will be present throughout the life of the infected T
cell in vivo.
Whether integrated or not, the HIV-1 promoter is capable
of limited transcription prior to the production of Tat, the
viral transactivating protein [76]. This pre-Tat transcrip-
tion is necessary to initiate HIV-1 expression, and in the
case of the integrated provirus, to complete the replication
cycle. Once initial Tat is produced from an integrated pro-
virus, a positive feedback loop is initiated that increases
HIV-1 expression by about 3 orders of magnitude. In the
case of uDNA, the sensitivity of the HIV-1 promoter to Tat
transactivation is reduced dramatically in comparison
with the integrated provirus, and the virus does not repro-
duce. The reasons for the low expression from uDNA are
not well understood at the mechanistic level, but as pro-
tection from intracellular parasites it is clearly to the cell's
advantage to favor transcription from chromatin rather
than from extrachromasomal nuclear DNA. We observe
about a 10 fold increase in total uDNA gene expression in
response to Tat. However, our single cell analysis reveals
that the majority of this increase is the result of activation
of previously latent genomes, seen as an increase in the
number of cells displaying uDNA gene expression, rather
than an activation of uDNA to the high level of expression
achieved by iDNA.
Gene expression from uDNA might generate proteins that
are functionally or antigenically different from those
expressed from the integrated provirus, with several possi-
ble consequences. We have shown that phenotypic com-
plementation occurs between integrated and non-
integrated viruses, through the packaging and delivery of
uDNA-derived genomes into target cells and the integra-
tion of these genomes into target cells. We observed a high
frequency of integration by integrase mutant viruses in the
second round of replication, which must result from com-
plementation by WT integrase. It also seems likely that the
unintegrated virus could complement functions of the
integrated virus, though this awaits further study.
A coinfecting virus may positively influence the replica-
tion of a second virus (as we have shown) or alternatively
it might negatively influence another virus within the
same cell. Whether viral interactions are positive or nega-
tive will depend on several factors. It seems possible or
even likely that coinfecting viruses may compete for cellu-
lar resources such as transcription factors or other cellular
components essential for virus expression, transport and
assembly. In addition, dominant negative variants of viral
proteins could inhibit replication of all viruses within a
cell [77]. It might be useful to exploit such an interfering
mechanism to therapeutically intervene in HIV-1 infec-
tion [78] with non-integrating lentiviral vectors [79,80].
Such vectors might be able to persist for some useful
length of time through the coinfection complementation
mechanism we describe here, as a form of vector mobili-
zation [81,82]. An obvious potential disadvantage to rep-
lication of non-integrating vectors would be unintended
recombination with the "native" viruses.
Another potential consequence of uDNA gene expression
might be expansion of the repertoire of HIV-1 antigens
presented to the immune system [10,28,50]. Our findings
support this possibility and point to the prospect that
through uDNA activation during coinfection, cells may
more frequently present a diverse collection of epitopes
than previously considered.
The high proportion of inactive but rescuable uDNA
genomes makes it tempting to speculate that uDNA may
constitute a reservoir of latent virus in cells that can be
recruited into the replicating virus population by reinfec-
tion. In fact, circular forms of uDNA are highly stable and
are only lost through dilution during cell division or by
death of the infected cell [30,34,35]. Since macrophages
and resting T cells do not replicate, they could provide an
ideal environment for such a reservoir that has the poten-
tial to be substantially larger than the documented reser-
voir of integrated proviruses within resting T cells [5,83].
In this context it is important to note that gene expression
from uDNA is substantially higher in non-proliferatingRetrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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cells than in actively replicating cells [27]. In addition, a
recent study has shown that both linear and circular
uDNA can persist in macrophages for at least 30 days [32].
Elegant studies from the Siliciano group and others have
described a form of pre-integration latency, where activa-
tion of resting cells soon after infection allows virus inte-
gration and productive infection to proceed [69,84]. This
form of latency lasts only a day or two and depends upon
the PIC remaining functional so that it can mediate viral
integration. In contrast, the form of latency we propose
depends only on the uDNA remaining competent for
transcriptional activation by an incoming virus.
To limit the generation of uDNA by the WT viruses, we
kept infection rates to the lowest levels feasible, frequently
employing an MOI of ≤0.05. However, we have not quan-
tified how much uDNA was generated by the integrase-
WT viruses, nor do our calculations consider possible
uDNA generated by the WT viruses. In the virus transfer
experiments (Figure 5) we employed a wide range of MOI
and ratios of WT to D116N in part to control for this var-
iable. For the most part the packaging efficiency of the
D116N genomes was independent of the ratio of WT to
D116N viruses used to infect producer cells and was
directly linked with the appearance of doubly infected
producer cells. A partial exception to this rule was virus
generated day 3 after infection of primary T cell producers,
where there was some reduction in D116N replication
when a high ratio of D116N to WT was employed (Figure
5E). The variability of the data also increased considerably
between days 2 and 3, though there was no statistical sig-
nificance between the aggregate results from each day. By
day 3 activated T cells will have divided up to two times,
diluting the D116N uDNA genomes but not the inte-
grated proviruses, which replicate with the cellular DNA.
This effect seems to be more apparent in cells with a high
D116N copy number. A more thorough parsing of these
relationships is currently underway.
This study and prior studies observe that uDNA is never as
strong a template for gene expression as iDNA. Yet uDNA
is able to successfully compete with the integrated provi-
rus for packaging into infectious virions. In fact, uDNA
seems to be as efficient as integrated virus at producing
genomes that are packaged into virions. What accounts
for this dichotomy? Apparently uDNA-derived full length
RNA is able to associate with the machinery of viral
assembly more efficiently than iDNA-derived RNA. We
hypothesize that the higher rate of iDNA transcription
consumes the local supply of some necessary and limiting
factor(s) faster than it/they can be provided, while the
lower production rate of uDNA transcription more closely
matches the availability of the factor(s). Studies are under-
way to test this hypothesis.
Such competition for limited cellular resources would not
necessarily counteract the type of "beneficial" cooperativ-
ity (to the virus) which we have described. On the con-
trary, by successfully competing with integrated
proviruses, "disadvantaged" members of the viral popula-
tion, i.e. viruses with some functional defect, or viruses
that are otherwise functional but which fail to integrate
for stochastic reasons, would be able to contribute to the
replicating population. The advantage to this would be
the preservation of extant genetic diversity, lowering of
genetic drift, an increase in effective population size, and
the promotion of further diversification and evolution.
On theoretical grounds at least, each of these would ben-
efit viral fitness and contribute to viral persistence. There
is also evidence that diversity of HIV-1 itself, apart from
selective advantages of individual strains which might
arise, promotes viral persistence [85,86]. The replication
of unintegrated HIV-1 could contribute to such a process.
Also within the realm of speculation, sequential infection
of cells might favor the viruses which infect after initial
productive infection. If a cell already contains Tat, Rev and
virion components undergoing assembly, an incoming
virus might gain a kinetic advantage by skipping integra-
tion. The time required for integration would be sub-
tracted from the time required to complete its replication
cycle. Although virus-induced CD4 down modulation can
prevent reinfection, it takes a day or two for a cell to be
resistant to reinfection, during which time incoming
viruses might be at a selective advantage through virus
complementation such as we have described.
Methods
Viruses
Schematic diagrams of all reporter viruses can be found in
Additional File 1: Virus schematics. Fluorescent protein
reporter viruses bearing genes for EGFP (GFP), EYFP (YFP)
and ECFP (CFP) cloned between the envelope and nef
open reading frames have been previously described
[43,55]. Nef expression is driven by an IRES element
between the reporter gene and nef. All virus constructs are
based on HIV-1 NL4-3. DsRed-Express (DsRedX)-contain-
ing viruses were constructed in an identical manner using
the DsRed-Express gene from Clontech. Replication-com-
petent NLENG1-IRES (containing GFP), NLENY1-IRES
(containing YFP), NLENC1-IRES (containing CFP) and
NLRX-IRES (containing DsRedX)) and replication-defec-
tive viruses containing two stop codons in the envelope
reading frame (NLENG1-ES-IRES, NLENY1-ES-IRES,
NLENC1-ES-IRES and NLRX-ES-IRES) were constructed
for each reporter virus [43]. For simplicity, in this report
we designate all GFP viruses as either WT-GFP or D116N-
GFP to indicate the status of the integrase gene. Similar
nomenclature is used for all viruses. For single round
infection assays, envelope defective viruses were pseudo-
typed with VSV-G protein. Envelope-defective dualRetrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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reporter viruses were constructed by substituting the
region of NL-r-HSAS which contains the murine CD24
(HSA) gene in place of vpr [59] into NLENG1-ES-IRES
and NLENG1-ES-IRES-D116N, and are named virus NLH-
GESI and NLHGESI-D116N for correspondence purposes.
In data presentation they are designated WT-GFP/HSA
dual reporter and D116N-GFP/HSA dual reporter virus,
respectively. The D116N integrase mutation was con-
structed by recombinant PCR, which introduced a single
G to A base pair substitution in the first nucleotide of inte-
grase codon 116, changing it from aspartic acid to aspar-
agine. A translationally silent BamHI restriction site was
also introduced 8 bp downstream of the G->A mutation
which allows confirmation of cloning by restriction diges-
tion.
HIV-1 virus stocks were generated by transfection of 293T
cells as described [43] except that cells were transfected
with FuGENE 6 (Roche) or polyethylenimine (PEI)
(Sigma) [87]. Infections were typically performed below
an MOI of 0.2. An exception is in Figure 5 where up to an
MOI of 1.6 of WT virus was employed in order to generate
an infection response curve at a wide range of infection
rates. When required for PCR, virus stocks were treated
with DNase (Invitrogen) at 10 U/ml for 30 minutes at
room temperature. VSV-G pseudotyping of envelope-
defective viruses was performed by cotransfection of 293T
cells with a VSV-G expression plasmid (Clontech) at a
HIV/VSV-G plasmid ratio of 8:1. For Vpr complementa-
tion of Vpr-negative viruses, an NL4-3 Vpr expression
plasmid was cotransfected with NLHGESI (WT-dual
reporter virus) or NLHGESI-D116N (D116N-dual
reporter virus). For virus transfer assays, 9–18 hours after
infection of producer cells, residual input virus was
removed by a cell wash in Hanks basal salt solution
(HBSS) followed by a 10 minute incubation with 1 mg/ml
pronase in HEPES-buffered HBSS for 10 min at room tem-
perature, followed by two washes in complete medium.
One day and two days later supernatants were collected,
cells and debris removed by centrifugation at 1000 g for
10 minutes, then these supernatants were used to infect
Jurkat-Tat cells. Infections were performed in the presence
of 10 μg/ml DEAE dextran, or alternatively target cells
were infected via spinoculation of virus transfer superna-
tants by centrifugation at 1200 g for 2 hours at 25°C [88].
Integrase inhibitor 118-D-24 (200 μM), Zidovudine
(AZT) and Efavirenz (1 μg/ml each) were applied at the
time of infection where indicated. Stock solution of 118-
D-24 was prepared in DMSO at 100 mM. Where indi-
cated, Indinavir sulfate (2 μM) was applied to cells within
12 hours of infection. Collection of day 3 viruses was
done following a medium change on day 2. All antiviral
compounds were obtained from the NIH AIDS Reagent
Repository.
Cells
293T was from the American Type Culture Collection. Jur-
kat (clone EL-6), and Jurkat-Tat were from the ARRRP. Jur-
kat-Tat cells were used only after selection in G418
(Sigma) to maintain Tat expression. 293T was maintained
in Gibco Advanced (reduced serum requirement) DMEM
with 5% fetal bovine serum (FBS) plus penicillin and
streptomycin and 50 μM β-mercaptoethanol; Jurkat and
Jurkat-Tat were cultured in Gibco Advanced RPMI-1640
with 5% FBS plus penicillin and streptomycin and 50 μM
β-mercaptoethanol;. Primary CD4+ T cells were cultured
in the same medium as Jurkat except with 10% FBS. Pri-
mary CD4+ T cells were generated from healthy HIV-neg-
ative donor PBMC isolated by Ficoll-Hypaque
centrifugation, followed by negative selection of plastic-
adherent cells. CD8+ cells were next removed using anti-
CD8 magnetic Dynabeads (Dynal) and the remaining
non-adherent cells were stimulated with anti-CD3/CD28
T Cell Expander DynaBeads (Dynal) as per the manufac-
turer's instructions for 1–3 days prior to infection. IL-2
(50 U/ml) (obtained from the NIH) was added 24 hours
after bead stimulation and at every medium change.
Flow cytometry
Flow cytometry was performed on a Becton-Dickinson
FACSort upgraded to contain 488 nm, 407 nm and 637
nm lasers and 5 fluorescence detectors (Cytek Develop-
ment). GFP and YFP were detected in FL-1 and FL-2 using
505/5 and 550/30 filters, respectively, and a 540SP dich-
roic splitter. CFP was detected using a 575/15 filter off the
407 nm laser. Compensation was applied during data col-
lection based on single color controls. Data collection was
with CellQuest Pro software for the Mac (BD Biosciences).
Flow data was analyzed using FlowJo 8 for the Mac (Tree
Star). HSA expression was analyzed using APC-conjugated
anti-mCD24 antibody, clone M1/69 (BioLegend). Twenty
four hours prior to staining, cells were pronase treated as
described above to remove any mCD24 (HSA) deposited
onto cell membranes by virions during initial infection.
HIV-1 p24 Gag ELISA
ELISA assays were performed using reagents and protocol
kindly provided by Susan Zolla-Pazner, New York Univer-
sity [89]. Briefly, a sandwich ELISA employs 96 well plates
coated with anti-p24 human mAb 91–5. Detection of
bound p24 is performed using biotinylated anti-p24
human mAb 241D. Plates were developed using a strepta-
vidin-alkaline phosphatase ELISA amplification system
(Invitrogen) and read at 490 nm. All samples were run in
duplicate with SD <10%.
Quantitative Real Time PCR for DNA and RNA
DNA PCR
DNA was isolated from infected cells using the DNeasy
Blood & Tissue kit (Qiagen) and RNase A RNA digestionRetrovirology 2008, 5:60 http://www.retrovirology.com/content/5/1/60
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(Sigma R4642). Quantitative real-time DNA PCR was per-
formed using the QuantiTect Probe PCR kit (Qiagen) and
primers and TaqMan probes (Integrated DNA Technolo-
gies) specific for GFP [90], DsRed [91] HSA [92] and β-
globin [93] that have been described previously. Amplifi-
cation and detection were performed on a Chromo4 real-
time PCR machine (Bio-Rad) and analyzed using the
manufacturer's Opticon Monitor software. A reference
standard for determination of cell numbers by amplifica-
tion of β-globin was generated using DNA isolated from
uninfected Jurkat cells, quantitated by spectrophotometry
and serially diluted (range 1400-1.4 cells/μl, linear range
in PCR 1400-14 cells/μl, r2 > 0.99). To quantitate relative
amounts of GFP, DsRedX and HSA nucleic acids we devel-
oped DNA and RNA target sequences carrying one copy of
each PCR target, guaranteeing equal stoichiometry of each
target for relative quantification of unknowns. To generate
this standard, the GFP, DsRed and HSA target DNA
sequences were amplified by PCR then linked using
recombinant PCR. For RNA production (see below) a T7
promoter was introduced at the 5' end of this sequence, in
the order: T7p-GFP-DsRedX-HSA (called "T7GRH stand-
ard"), yielding a 279 bp product. For DNA PCR, this PCR
product was purified following agarose gel electrophore-
sis, quantitated by spectrophotometry and serially diluted
to generate a standard curve (range 100,000-1 copies/μl,
linear range 100,000-10 copies/μl, r2 > 0.99).
qPCR for integrated HIV-1 DNA was performed using
Alu PCR as previously described [13,94] on an ABI 7200
real time PCR machine. Briefly, total nucleic acids from
infected cells were extracted in urea lysis buffer then
extracted by phenol/chloroform and precipitated with
ethanol. Two nested PCR reactions were performed, then
first using an Alu forward primer (5'-GCCTCCCAAAGT-
GCTGGGATG-3') and HIV-1 gag reverse primer (5'-
GCTCTCGCACCCATCTCTCTCC-3'). The second PCR
amplification employed internal primers and probes SR1
forward primer, M667 reverse primer and ZXF probe pre-
viously described [93]. A standard curve representing inte-
grated HIV sequences was generated from cells infected
with a nonspreading HIV-based reporter vector. In control
experiments, there was no background from noninte-
grated viral DNA, and values for integrated DNA copies
varied less than 20% within triplicates. The β-globin
standard was used to determine the approximate number
of proviruses per cell (used the same primer-probe set as
in the previous section).
RT-PCR
RNA was isolated from virus-containing culture medium
or from infected cells using the RNeasy Mini Kit (Qiagen)
(including QIAshredder homogenization and on-column
DNase treatment). Quantitative real-time reverse tran-
scriptase (RT) PCR was performed using primers and Taq-
Man probes (Integrated DNA Technologies) specific for
GFP [90], DsRed [91] and β-2 microglobulin [95,96],
with the QuantiTect Probe RT-PCR kit (Qiagen). No-RT
controls were included for each RNA preparation. Ampli-
fication and detection were performed on the Chromo4
instrument. For relative quantification of GFP and
DsRedX RNA, a T7-promoted transcription reaction was
run off the T7GRH standard DNA using the Riboprobe in
vitro transcription kit (Promega). Residual DNA was elim-
inated by DNase digestion, then the RNA was purified
using the RNeasy Mini Kit, quantitated by spectropho-
tometry and serially diluted to generate a standard curve
(range 10,000,000-1 copies/μl, linear range in RT-PCR
was 10,000,000-100 copies/μl, r2 > 0.99). RT-PCR on vir-
ions: Virus-containing culture supernatants were either
directly lysed in RNA extraction buffer for RT-PCR or first
RNase treated to remove non-virion-associated RNA. No
effect on HIV-1 RNA copy number resulted from prior
RNase treatment, while free cellular β-2 microglobulin
was typically reduced from about 4 cell equivalents to 2
per 50μL of sample. HIV-1 RNA copy number was ≥1000
fold greater than cellular β-2 microglobulin in culture
medium, while cellular extracts contained 20 to >100 fold
excess of β-2 microglobulin mRNA vs. HIV-1 RNA, a 5
orders of magnitude shift. These controls demonstrate
that PCR amplification was specific for virion-packaged
RNA.
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